Key result
Transcatheter interventions provide effective surgical alternatives for women with CHD despite sex-specific risks.
Why the study?
Women have historically been underrepresented in cardiovascular disease research, limiting generalizability and contributing to outcome disparities, with women with congenital heart disease being an even more vulnerable population.
Women with congenital heart disease face unique anatomical and physiological challenges during structural heart interventions, necessitating tailored approaches and improved representation in clinical trials.
May inform transcatheter choices for women with congenital heart disease; leaves open gaps in trial equity and sex-specific risk data.
PURPOSE OF REVIEW: To provide a review of current transcatheter interventions in women with congenital heart disease, with a focus on sex-specific considerations in diagnosis, management, and follow-up. RECENT FINDINGS: As the field of pediatric cardiology advances and patients with previously life-limiting diagnoses now survive well into adulthood, there is a growing need to pursue management strategies that improve quality of life. Unfortunately, in the treatment of cardiovascular disease, women have historically been underrepresented in research studies and clinical trials, which may limit the generalizability of available evidence and contribute to disparities in outcomes. Women with congenital heart disease (CHD) are an even more vulnerable population given the relatively low prevalence of CHD. This review discusses several CHD lesions and current trends in diagnosis, management, and follow-up in women. Additionally, it highlights sex-specific considerations in this unique patient population. Future initiatives and applications that may help improve the lifetime care of women with CHD are also reviewed. Although there have been increasing efforts to improve the inclusion of women in medical research in recent years, substantial gaps in representation remain. As emerging technologies are increasingly introduced in the CHD field, there is an important opportunity to improve the representation of women in studies evaluating procedural outcomes. Tools such as artificial intelligence and machine learning may help facilitate scalable screening and risk-stratification strategies for women with CHD.
No takes yet. Share an insight, caveat, or question.
Coppola et al. (2026) conducted a review in Congenital heart disease. Transcatheter structural heart interventions was evaluated. Transcatheter interventions provide effective alternatives to surgery for women with congenital heart disease, though women remain underrepresented in clinical trials and face sex-specific procedural risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: